GENEWIZ and Nashville Biosciences Announce Collaboration to Combine Biobank DNA Samples and Next Generation Sequencing

NASHVILLE, TN and SOUTH PLAINFIELD, NJ – October 16, 2018 Nashville Biosciences, a robust and highly-skilled bioinformatics and genomics company, and GENEWIZ (ASHG, booth #1237), a leading global genomics service provider, today announced at the American Society of Human Genetics (ASHG) Conference a new collaboration that will streamline researchers’ access to biological insights by combining Nashville Biosciences’ BioVU® biobank with GENEWIZ’s next generation sequencing.

Created and housed at Vanderbilt University Medical Center, BioVU contains over 250,000 DNA samples and 2.8 million de-identified patient records that reflect the broad diversity of the human population, ensuring more accurate research results. Paired with GENEWIZ’s industry-leading next generation sequencing, this creates a solution that accelerates precision medicine research by providing everything from project consultation and design to bioinformatics of results.

“Nashville Biosciences’ BioVU technology, coupled with GENEWIZ’s expertise and experience with next generation sequencing, will provide researchers a wealth of high-quality, annotated human samples adding statistical power to their retrospective cohort studies,” remarked Dr. Ginger Zhou, Vice President, Global Next Generation Sequencing for GENEWIZ.

Dr. Leeland Ekstrom, Chief Operating Officer and Founder of Nashville Biosciences, commented, “We are excited to be working with GENEWIZ to simplify the research process by harnessing the power of BioVU along with GENEWIZ’s high-throughput sequencing capabilities to encourage the rapid discovery and development of precision drugs and therapeutics.”

Learn more about the collaboration by visiting GENEWIZ at booth #1237 at the American Society of Human Genetics (ASHG) Conference, taking place October 16-20 in San Diego, CA. The conference will also feature scientific posters, including “Kidney Genome Atlas: a whole-genome landscape of more than 2,000 kidney disease patients” which presents research conducted by scientists from Goldfinch Bio, Nashville Biosciences, et al.

For more information on next generation sequencing with GENEWIZ, visit:

For more information about Nashville Biosciences and BioVU®, visit:


GENEWIZ is a global leader in genomics services that enable research scientists within pharmaceutical, biotechnology, agriculture, environmental and clean energy, academic, and government institutions to advance their discoveries. Customers rely on our unique and proprietary genomics technologies and services, backed by our specialized experts in Sanger sequencing, gene synthesis, molecular biology, next generation sequencing, bioinformatics, and GLP regulatory-compliant services.

Headquartered in South Plainfield, NJ, GENEWIZ is privately-held with a network of laboratories in Boston, MA; Washington, D.C. Metro; Research Triangle Park, NC; San Diego, CA; San Francisco, CA; and Seattle, WA. International locations include Beijing, Suzhou, Tianjin, and Guangzhou, China; Takeley, United Kingdom; Leipzig, Germany; and Tokyo, Japan. For more information, visit, and connect with us on LinkedIn, Twitter, Facebook, YouTube, WeChat, and Weibo.


Nashville Biosciences, a wholly owned subsidiary of Vanderbilt University Medical Center (VUMC), was created to harness the Medical Center’s extensive genomic and bioinformatics resources for drug and diagnostics discovery and development. Leveraging Vanderbilt University Innovation™, Nashville Biosciences serves as a commercial interface between outside companies and the formidable research capabilities housed within VUMC, including BioVU®, one of the world’s most comprehensive genetic databases linked to de-identified medical records with years of longitudinal clinical data. This unique asset is one of the largest and highest quality of its kind, providing an unprecedented opportunity to guide R&D activity in biotech, pharma, diagnostics, medical devices and other life sciences applications.

Lindsay Kendall-Zuill

John Howser